The H1 healthcare data platform sells physician and provider intelligence to pharma companies, hospital systems, health plans, and digital health firms. H1 has now raised a new $40 million round led by CVS Health Ventures at a moment when older SaaS startups are getting ignored and AI-native companies are soaking up most of the hype. The pitch is simple: fragmented doctor data still creates expensive mistakes, and that problem hasn’t gone away just because generative AI showed up. Founded in New York in 2017 by Ariel Katz and Ian Sax, H1 is trying to prove that a real data moat still matters.
What does the H1 healthcare data platform do?
The H1 healthcare data platform is basically a giant operating layer for figuring out which doctors matter for a given healthcare decision. A customer starts with a question — which physicians lead research in a disease area, which trial sites have the right investigators, which doctors prescribe a therapy, or which providers are actually in-network. H1 pulls together fragmented healthcare professional, clinical, scientific, and provider data. Then it turns that into searchable profiles and workflow-specific recommendations.
That data is packaged into product lines instead of one generic dashboard. H1 for Medical helps medical affairs teams find and engage key opinion leaders. H1 for Clinical is built around site selection and principal investigator discovery. It also covers participant recruitment and more representative trials. H1 for Commercial is aimed at helping life sciences teams launch therapies and improve patient access. After the Ribbon deal, H1 also added H1 for Health Plans & Digital Health, pushing deeper into accurate provider data for insurers and care-navigation companies.
That’s the part Katz is leaning on in the AI debate. A workflow layer can get copied fast. A global, constantly refreshed doctor and provider knowledge base is harder to fake. H1 frames the product around operational questions customers ask every day — who should run a trial, who is emerging in a specialty, which hospital has prior trial activity, and whether a provider directory is actually accurate.
Before tools like this, a lot of that work lived in spreadsheets, vendor files, rep notes, public registries, and manual phone verification. On the payer side, H1 now talks openly about directory management and rosters. Credentialing, network management, and provider data management are core workflows too. That’s not glamorous software. But it’s the kind of operational plumbing big healthcare organizations spend years trying to clean up.
Who founded H1 and why did it start?
H1’s founding story
H1 was started in 2017 by Ariel Katz and Ian Sax. The company’s core idea was that healthcare runs on relationships and expertise, yet the information needed to find the right doctor was scattered, stale, and oddly manual. H1 built around that gap from day 1 — not as a generic CRM layer, but as a data company built to connect life sciences teams, providers, payers, and patients with the right healthcare professional faster.
Why Ariel Katz looked credible from the start
Katz wasn’t a first-time founder learning how to sell software on the fly. Before H1, he started ResearchConnection while still in college, and that company expanded to more than 40 universities before being acquired. That matters because H1’s model depends on building structured information products, not just shipping a pretty interface. Katz had already shown he could organize messy institutional data into something customers would actually pay for.
Traction, product expansion, and the shape of the business
H1 looks a lot less like a small startup now than it did during its Y Combinator days. The company has more than 300 employees, customers across 6 continents, and over 200 customers. It also has 6 of the top 20 pharma companies as customers, and after its Veda acquisition it now powers 9 of the top 10 health plans in America. Earlier reporting pegged H1’s data network at more than 10 million healthcare professionals.
H1 has also used acquisitions as a way to get broader, not just bigger. It bought Ribbon Health to expand into health-plan and digital-health provider data. Then it bought Veda to deepen payer-side capabilities like rosters and network management. That’s a clear signal that H1 wants to own more of the provider-data stack, especially on the payer side where directory accuracy is both operationally painful and commercially valuable.
Fundraising and competition
The new round is $40 million, and CVS Health Ventures led it. That came after H1 had already turned cash-flow and EBITDA profitable in 2025 and while management was forecasting growth of more than 40% for 2026. Katz told TechCrunch the company wasn’t actively looking to raise, which makes this feel more like a strategic partnership round than a rescue. H1’s last disclosed valuation was $750 million, set when Altimeter Capital led a $100 million round in November 2021.
Competition is real, even if it’s not flashy. Definitive Healthcare is the most obvious public comp in healthcare commercial intelligence, and big incumbents like IQVIA have long sold data-heavy products into life sciences and provider organizations. The older alternative is even tougher to kill: internal teams stitching together public records, third-party files, CRM notes, and lots of manual checking. H1’s differentiation is that it spans clinical, medical, commercial, and payer workflows with one data foundation. That’s why Katz argues, “If you’re a workflow SaaS company, you could vibe code that.”
Why are investors backing the H1 healthcare data platform now?
This round matters because it says something specific about what investors still want. H1 didn’t raise on a “we have AI” story alone. It raised after getting profitable, after building a large customer base, and after proving it could widen its footprint through acquisitions. In a market where lots of pre-2022 software companies are getting treated like leftovers, that’s a real signal.
CVS is also not a tourist investor. CVS Health Ventures was launched with $100 million to back companies that can make healthcare more accessible, affordable, and simpler, and H1 now sits right in the middle of provider data, payer operations, and digital navigation. If CVS ends up becoming more than a cap-table partner — say, a distribution or product partner across Aetna-aligned workflows — this round could matter more than its size suggests.
There’s a second message here. Katz’s other line from the TechCrunch interview was, “I don’t worry about Claude ever doing what we do.” That sounds a little self-serving. It’s also not crazy. The interface layer in software is getting cheaper fast. But proprietary, normalized healthcare data that works across pharma, trials, and insurance is still expensive to build and even harder to maintain.
How big is the market for healthcare data platforms?
The category is large enough that H1 doesn’t need to own all of it to build a big company. IMARC estimates the U.S. healthcare big data analytics market was worth $24.71 billion in 2025 and projects it will reach $62.43 billion by 2034. Grand View Research, looking at U.S. healthcare business intelligence, expects a 13.3% CAGR from 2025 to 2030. Those aren’t niche-software numbers. They describe a big, still-expanding budget line inside healthcare.
Because more healthcare decisions are becoming data problems, the timing makes sense. Clinical trial teams want faster site selection and better patient representation. Medical affairs groups want better KOL mapping. Health plans need cleaner provider directories and stronger network data. And AI only increases the value of dependable underlying data — if the source layer is wrong, the fancy model on top just produces faster nonsense. Interoperability pressure, cloud adoption, and broader digitization across health systems all push buyers toward platforms that can normalize messy data.
What comes next for H1 healthcare data platform?
H1 isn’t selling a dream of replacing healthcare with AI magic. It’s selling the less sexy claim that accurate doctor and provider data is still hard to build, hard to maintain, and worth real money. That’s a much better business argument. For the H1 healthcare data platform, the next thing to watch isn’t just revenue growth — it’s whether the CVS relationship turns into deeper payer distribution and whether H1 can keep turning acquisitions into one coherent product stack.
Read how Corgi raised a $106M Series B1 at a $2.6B valuation to rebuild startup insurance with AI-native underwriting, same-day coverage, and software-first workflows.
FAQ
– What funding did H1 just raise?
H1 raised $40 million in a round led by CVS Health Ventures in May 2026. What makes the round interesting is that H1 said it wasn’t out shopping for capital — the company was already cash-flow and EBITDA profitable in 2025, which makes this look more strategic than defensive.
– How does H1’s platform actually work?
H1 works by aggregating doctor, clinical, scientific, and provider data into one searchable system that customers can use for specific healthcare workflows. A pharma team might use it to identify key opinion leaders or trial investigators. A health plan might use it to clean up provider directories, manage rosters, or improve network data.
– Who founded H1?
H1 was founded in 2017 by Ariel Katz and Ian Sax. Katz had already built one startup before H1 — ResearchConnection — which grew to more than 40 universities, giving him a real track record in turning messy information problems into software products.
– What market is H1 competing in?
H1 sits in the healthcare data, healthcare analytics, and commercial intelligence category, with overlap into provider data management for payers. That puts it up against specialist data vendors and broader healthcare intelligence incumbents. It also faces the oldest competitor of all: internal teams still relying on fragmented files, public records, and manual verification.
